The 2022 AHA/ACC/HFSA guideline also has recommended the use of SGLT2 inhibitors in patients with chronic symptomatic HF with or without type 2 diabetes to reduce CVD mortality and HF hospitalization [4]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.